Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II), a company that specializes in cancer monitoring, has achieved an important milestone in the commercialization of DiviTum® TKa in the United States with the receipt of a PLA code from the American Medical Association (AMA). This is a major step forward in the quest for providing patients in the US with access to a reliable cancer monitoring solution.
The DiviTum® TKa test has a unique PLA code issued by the American Medical Association. Starting October 1st, 2023, this code will be used by providers and payers to process and report healthcare claims, making the process easier and more efficient. Make sure to utilize the new code for optimized success!
We are thrilled to have been granted a PLA code by the AMA, a major milestone in our endeavor to drive better pricing transparency and patient access. With the presentation of this code, government and commercial payers in the US can now incorporate our price determination process for Medicare into their contracts and reimbursement processes.
This is especially meaningful to the 50% of women survivors of this cancer who are Medicare beneficiaries, as they will now benefit from clear and accessible pricing.
Biovica – Treatment decisions with greater confidence
Biovica is dedicated to improving the care of cancer patients – through its innovative blood-based biomarker assays, DiviTum® TKa. This cutting-edge test, which is FDA 510(k) cleared in the US and CE-marked in the European Union, is able to provide valuable insights into the effectiveness of therapy for metastatic breast cancer patients.
Biovica has been collaborating with world-leading cancer institutes and pharmaceutical giants to make this possible, and its shares are now being traded on the Nasdaq First North Premier Growth Market (BIOVIC B) – where FNCA Sweden AB serves as a Certified Adviser.